# Etiological Heterogeneity in Sporadic ALS: Current Hypotheses and Proposed Subgroups > **Scope:** Sporadic amyotrophic lateral sclerosis (sALS) accounts for ~90% of all ALS cases and has no identified causal germline mutation. This document synthesizes the strongest current hypotheses about etiological heterogeneity within sALS, identifies proposed subgroups based on biomarkers, clinical phenotype, or environmental exposure, and assesses the evidence for each. It also identifies a sub-population that may be tractable for a focused trial. --- ## 1. Executive Summary Sporadic ALS is now widely understood as a syndrome rather than a single disease entity. Current evidence supports a **"multistep" model** in which genetic susceptibility, environmental exposures, aging-related processes, and stochastic molecular events converge over decades to produce symptomatic disease. Within sALS, multiple **etiological axes of heterogeneity** have been proposed: 1. **Pathological proteinopathy axis** (TDP-43 proteinopathy vs. non-TDP-43) 2. **Neuroanatomical onset phenotype axis** (bulbar vs. limb; upper vs. lower motor neuron-predominant) 3. **Clinical trajectory axis** (fast vs. slow progressors) 4. **Comorbidity axis** (ALS-FTD spectrum vs. pure motor neuron disease) 5. **Biomarker-defined axis** (NfL-high vs. NfL-low; epigenetic signature-positive) 6. **Environmental exposure axis** (military/service-related, athletic, etc.) 7. **Immunometabolic axis** (autoimmune-antibody positive; microbiome-altered) 8. **Somatic mosaicism / cryptic genetic axis** The evidence for these subgroups ranges from robust pathological stratification to emerging biologically-defined subsets. Critically, the **TDP-43-positive, NfL-elevated, rapidly progressing subgroup** appears most immediately tractable for biomarker-stratified trials. --- ## 2. Overarching Conceptual Framework: The Multistep Model A foundational hypothesis for understanding sALS heterogeneity is the **multistep model of ALS** (recently discussed in PMID: 41750236). This framework proposes that sALS results from the accumulation of 5–6 impactful biological "steps" over decades, whereas familial ALS with high-penetrance mutations (e.g., *SOD1*, *FUS*, *C9orf72*) requires fewer steps because the causal mutation already constitutes a major step. **Key implications for heterogeneity:** - **Step modifiers** (environmental exposures, trauma, aging, senescence) lower the threshold for step acquisition and influence the anatomical site of onset. - **Timing, duration, and cumulative effects** of specific steps vary between individuals, producing diverse clinical presentations. - The model integrates genetics, environmental exposures, and systems-level vulnerability into a single framework, accommodating both common and rare risk factors. **Assessment:** The multistep model is primarily a conceptual framework rather than a directly testable mechanistic model. It is strongly supported by epidemiological observations (latent period, age dependence, interaction between risk factors) but the individual "steps" remain agnostic as to biological identity. It provides the most coherent organizing principle for sALS heterogeneity currently available. --- ## 3. Proposed Subgroups and Evidence Assessment ### 3.1 TDP-43 Proteinopathy vs. Non-TDP-43 ALS **Hypothesis:** The vast majority (~97%) of sALS cases show cytoplasmic inclusions of phosphorylated, C-terminally truncated TDP-43 in upper and lower motor neurons and frontal cortex. A minority shows no TDP-43 pathology and instead exhibits aggregation of FUS, SOD1, or unknown proteins. TDP-43 proteinopathy itself may be further stratified by phosphorylation state, fragmentation pattern, and C-terminal truncation. **Evidence Supporting:** - Autopsy studies consistently identify TDP-43 inclusions as the dominant pathological substrate in sALS. - TDP-43 inclusions are shared with frontotemporal lobar degeneration (FTLD-TDP), explaining the ALS-FTD spectrum. - Distinct TDP-43 biochemical species (phosphorylation at specific residues, C-terminal fragments) have been described and correlated with anatomical spread patterns. **Evidence Contraindicating / Nuances:** - TDP-43 pathology is found in other neurodegenerative diseases (e.g., FTLD, Alzheimer's, Limbic-predominant Age-related TDP-43 Encephalopathy / LATE), indicating it is not ALS-specific. - The relationship between TDP-43 aggregation and neurotoxicity is debated; some models suggest loss of nuclear TDP-43 function (rather than aggregation) drives toxicity. - A small subset of sALS has no identifiable proteinopathy, suggesting possible distinct etiologies. **Trial Tractability:** TDP-43 is not yet druggable in a specific way. However, TDP-43-negative subgroups (if identifiable antemortem) may represent distinct entities and should be excluded from TDP-43-targeted trials. Antibody-based TDP-43 clearance strategies are in preclinical stages. --- ### 3.2 Clinical Phenotype: Bulbar vs. Limb Onset; UMN vs. LMN Predominance **Hypothesis:** The site of symptom onset (bulbar vs. spinal) and the relative involvement of upper vs. lower motor neurons define etiologically distinct subgroups. **Evidence Supporting:** - Bulbar-onset ALS is associated with older age, more rapid progression, shorter survival, and higher frequency of cognitive/behavioral impairment. - Limb-onset ALS shows sex differences (male predominance), longer survival, and different patterns of muscle involvement (distal vs. proximal). - UMN-predominant forms (e.g., primary lateral sclerosis, PLS) have significantly longer survival and may represent a distinct biological entity, though many evolve to combined UMN/LMN ALS. - Spinal-onset forms are more heterogeneous, with flail limb, hemiplegic, and regional variants. **Evidence Contraindicating:** - Site of onset may reflect stochastic vulnerability of neuronal populations rather than distinct etiology. - Longitudinal studies show phenotype evolution (e.g., PLS → ALS; bulbar → generalized), suggesting a shared underlying process with variable anatomical expression. - Genome-wide association studies have not identified robust genetic loci specifically associated with bulbar vs. limb onset. **Trial Tractability:** Not ideal as a standalone stratifier. However, combining bulbar-onset with biomarker elevation (e.g., NfL) may identify a particularly aggressive subgroup where trial endpoints can be reached more quickly. --- ### 3.3 ALS-FTD Spectrum Endophenotypes **Hypothesis:** A substantial proportion of sALS patients (30–50%) exhibit frontotemporal cognitive or behavioral dysfunction that lies on a single clinico-pathological spectrum with behavioral variant FTD (bvFTD) and progressive non-fluent aphasia (PNFA). The comorbid ALS-FTD subgroup represents a distinct etiology with widespread TDP-43 pathology. **Evidence Supporting:** - Pathological identity: both ALS and bvFTD show TDP-43 inclusions (type A in most cases). - *C9orf72* repeat expansion carriers frequently show both phenotypes (though sALS without known repeat expansion also shows overlap). - Executive dysfunction and behavioral change are detectable early in disease course and predict worse prognosis. - Imaging studies reveal frontal atrophy in ALS-FTD overlap cases. **Evidence Contraindicating:** - Cognitive impairment in ALS may reflect executive network dysfunction due to widespread network disruption rather than a distinct Frontotemporal Dementia entity. - ALS-specific cognitive tests may be confounded by motor impairment. - Pure bulbar-onset cases may show language impairment that mimics FTD but reflects motor speech deficits. **Trial Tractability:** Moderate. ALS-FTD cases may be enriched for TDP-43 spreading mechanisms and could be candidates for anti-TDP-43 or anti-inflammatory trials. However, cognitive endpoints add complexity to trial design. --- ### 3.4 Neurofilament Light Chain (NfL)-Defined Subgroups **Hypothesis:** CSF and serum NfL levels identify a neuroaxonal injury subgroup with higher disease activity. NfL-High sALS represents a biologically and prognostically distinct entity. **Evidence Supporting:** - NfL levels are dramatically elevated in ALS compared to controls and inversely correlated with survival. - Longitudinal studies show NfL levels correlate with disease progression rate and treatment response (e.g., in Tofersen trials, NfL reduction tracked with clinical benefit). - NfL is being incorporated into adaptive trial designs and as a pharmacodynamic marker. - A recent study (PMID: 41928938) identified circulating cell-free DNA (cfDNA) methylation signatures that correlated with CSF neurofilament levels and disease progression, supporting a molecularly-defined progressive subgroup. **Evidence Contraindicating:** - NfL is not ALS-specific (elevated in multiple sclerosis, other neurodegenerative diseases, traumatic brain injury). - Very slowly progressive patients may have near-normal NfL, potentially creating floor effects. - The biological driver of NfL elevation may differ between genetic and sporadic cases. **Trial Tractability:** **High.** NfL-stratified trials are already being implemented. A focused trial in NfL-elevated, rapidly progressing sALS would have shorter follow-up, higher event rates, and a clear pharmacodynamic readout. This is arguably the most tractable sALS subgroup for near-term interventional trials. --- ### 3.5 Fast vs. Slow Progressors (Rate-Based Stratification) **Hypothesis:** The rate of ALS Functional Rating Scale-Revised (ALSFRS-R) decline divides patients into fast, intermediate, and slow progressors, with fast progressors representing a distinct biological entity rather than just the extreme of a normal distribution. **Evidence Supporting:** - Bimodal or multimodal distributions of progression rate have been reported in large cohorts. - Fast progressors show higher NfL, more pronounced neuroinflammation, and distinct transcriptomic signatures in blood and CSF. - Some slow-progressing cases survive >10 years and may represent a different or arrested biological process. **Evidence Contraindicating:** - Progression rate can change over time (plateau or acceleration), suggesting it reflects disease stage as much as intrinsic subtype. - Rate-based stratification is confounded by age, site of onset, and respiratory involvement. - Genetic influences on progression rate (e.g., *ATXN2* intermediate repeats, *UNC13A* variants) suggest some rate variation is modifiable by common variants rather than representing distinct etiologies. **Trial Tractability:** Moderate. A trial enriched for fast progressors reaches endpoints faster, but this introduces selection bias and may limit generalizability. Best used in combination with biomarker confirmation. --- ### 3.6 Somatic Mosaicism and Cryptic Genetic Subgroups **Hypothesis:** Low-level somatic mutations or repeat expansions in ALS/FTD genes (e.g., *C9orf72*, *SOD1*, *TARDBP*, *FUS*, *DYNC1H1*, *LMNA*) contribute to a subset of "sporadic" cases by creating focal, disease-driving mutations not detectable in blood. **Evidence Supporting:** - A landmark study (PMID: 41986690) used deep targeted sequencing of postmortem brain and spinal cord from 399 sporadic cases. Predicted deleterious somatic variants in ALS/FTD genes were observed in **2.1% of sporadic cases** lacking germline variants. These were typically focal, enriched in disease-affected regions, and present at very low allele fractions (<2%). - Long-read sequencing identified a de novo somatic *C9orf72* repeat expansion in one sFTD case. - Somatic variants in *DYNC1H1* and *LMNA* (genes associated with pediatric motor neuron degeneration) were detected by bulk RNA-seq in an independent cohort. - This suggests somatic "second-hit" or focal mutational events can drive widespread neurodegeneration, analogous to cancer. **Evidence Contraindicating:** - Only ~2% of cases explained, leaving the vast majority of sALS without an identified cryptic genetic cause. - Technical limitations (depth, tissue sampling, timing) mean this is likely an underestimate, but not dramatically so. - The causal relationship between low-frequency somatic variants and disease remains formally unproven for most identified variants. **Trial Tractability:** **Emerging.** If validated, somatic gene-panel testing on accessible tissue (CSF cells, skin biopsy) could identify an "occult genetic" subgroup amenable to gene-targeted therapies (e.g., ASOs). However, current technology is not ready for clinical trial stratification. Worth monitoring for future precision-trial designs. --- ### 3.7 Immune/Autoimmune and Neuroinflammatory Subgroups **Hypothesis:** A subset of sALS has an autoimmune or neuroinflammatory component, with antibodies against glycolipids (e.g., GM1, GD1a), ion channels, or CNS proteins, and activated microglial signatures. **Evidence Supporting:** - Antiganglioside antibodies (anti-GM1) are elevated in a minority of sALS patients, particularly those with predominantly lower motor neuron features. - CSF proteomics and PET imaging reveal heterogeneous microglial activation patterns. - Immunomodulatory trials (e.g., masitinib, NP001) have shown signals primarily in subgroups with elevated inflammatory markers. **Evidence Contraindicating:** - Anti-GM1 antibodies are neither sensitive nor specific for ALS (also seen in multifocal motor neuropathy and other conditions). - Multiple large immunomodulatory trials have failed in unstratified ALS populations. **Trial Tractability:** Moderate, contingent on better immune phenotyping. A trial enriched for anti-GM1-positive cases or those with elevated CSF inflammatory cytokines could be justified but requires robust pre-screening. --- ### 3.8 Oxidative Stress / Glutamate Excitotoxicity Subgroup **Hypothesis:** A subset of sALS is driven by excessive oxidative stress and impaired glutamate clearance, creating a positive feedback loop of motor neuron injury. **Evidence Supporting:** - *SOD1* mutations (familial) directly implicate oxidative stress pathways. - CSF glutamate levels are elevated in some sALS patients. - Riluzole, which modestly extends survival, acts partly via glutamate modulation. - Markers of oxidative stress (4-HNE, 3-nitrotyrosine) are elevated in sALS tissue. **Evidence Contraindicating:** - Riluzole has a modest effect (~2–3 months survival benefit), suggesting glutamate excitotoxicity is not the dominant driver in most cases. - Oxidative stress markers are downstream consequences of neurodegeneration rather than specific etiological drivers. - Antioxidant trials (e.g., vitamin E, coenzyme Q10) have been largely negative. **Trial Tractability:** Low. Without a robust biomarker to prospectively identify this subgroup, it remains challenging to target. --- ### 3.9 Microbiome and Metabolic Subgroups **Hypothesis:** Gut dysbiosis and microbially-derived metabolite alterations contribute to a distinct sALS subset, particularly via nicotinamide metabolism and systemic inflammation. **Evidence Supporting:** - ALS patients show reduced gut microbial diversity, with specific depletion of neuroprotective metabolite-producing species (e.g., *Akkermansia muciniphila* — discussed in PMID: 41752118). - Lower serum nicotinamide levels have been reported and correlated with disease severity. - Fecal microbiota transplantation and probiotic studies are under investigation. **Evidence Contraindicating:** - Dysbiosis may be secondary to diet changes, reduced mobility, and medications (e.g., riluzole, antibiotics). - Causal direction is uncertain; ALS mouse model studies show transferability of dysbiosis to healthy mice, but this is not conclusive in humans. - Heterogeneity of microbiome findings across studies (different cohorts, geographies, methodologies). **Trial Tractability:** Low-to-moderate. Metabolic stratification is feasible with serum metabolomics, but interventions (FMT, probiotics) are hard to blind and standardize. Not ready for a focused drug trial without better target validation. --- ### 3.10 Environmental Exposure Clusters **Hypothesis:** Specific environmental exposures define sALS subgroups, including: - **Military veterans / Gulf War service:** Elevated ALS incidence observed in deployed vs. non-deployed military populations. - **Professional athletes / head trauma:** Elevated risk in soccer, American football, and rugby players; chronic traumatic encephalopathy (CTE) TDP-43 pathology overlaps with ALS. - **Geographic clusters:** ALS prevalence varies by latitude and regional agricultural/industrial chemical exposure. - **Smoking, heavy metal, pesticide, and solvent exposure:** Epidemiologically associated with ALS risk. **Evidence Supporting:** - Veterans consistently show ~1.5–2× increased ALS risk. - Athletes show elevated rates, and some postmortem cases show CTE with ALS-like TDP-43 pathology. - Some geographic clusters (Western Pacific, Kii Peninsula) showed elevated ALS incidence linked to cycad toxin / environmental factors. **Evidence Contraindicating:** - No single environmental factor explains more than a small fraction of sALS cases. - Many associated exposures are correlated with socioeconomic status, physical activity, or trauma, making causal attribution difficult. - The Western Pacific cluster has largely disappeared, suggesting environmental factor reduction or genetic isolates. **Trial Tractability:** Low for direct intervention, but high for etiological study. Military/exposure cohorts could be enriched for specific toxin-related mechanisms if validated. --- ### 3.11 Axonal Transport / Cytoskeletal Vulnerability Subgroups **Hypothesis:** Impairment of axonal transport, particularly retrograde transport of signaling endosomes and mitochondria, represents an upstream, convergent vulnerability in ALS that may define a mechanistic subgroup. **Evidence Supporting:** - A comprehensive review (PMID: 41890591) argues that transport deficits are detectable presymptomatically across multiple ALS models (*SOD1*, *TARDBP*, *FUS*, *C9orf72*). Human iPSC-derived motor neuron data and neuroimaging in mutation carriers support early transport dysfunction in both familial and sporadic ALS. - *KIF5A* (kinesin heavy chain) mutations were identified as a novel ALS gene in 2018 and are associated with both familial and sporadic forms (PMID: 41760955), directly implicating cytoskeletal transport. - Distal "dying-back" axonopathy is a consistent feature, consistent with transport failure. **Evidence Contraindicating:** - Transport deficits are a common consequence of neurodegeneration, not necessarily an initiating event. - It remains unclear whether transport restoration alone is sufficient to halt disease. **Trial Tractability:** **Moderate-to-High.** Axonal transport biomarkers (e.g., pNfH, plasma NfL) are already measurable. Compounds that restore transport are in preclinical development. This represents a convergent mechanistic target that could span genetic and sporadic subtypes. --- ## 4. Cross-Cutting Themes and Integrative Framework ### 4.1 Convergence on TDP-43 but Divergence in Cause The dominant framework is that most sALS converges on TDP-43 proteinopathy as a common pathological endpoint, but via diverse upstream etiologies (genetic risk variants, environmental triggers, somatic mutations, aging, metabolic stress). This is analogous to other neurodegenerative syndromes (e.g., AD converging on amyloid/tau). ### 4.2 Biomarker-Informed Stratification Is the Most Tractable Near-Term Strategy The most actionable hypothesis is that **sALS can and should be stratified by biological activity** using fluid biomarkers (NfL/pNfH, GFAP, inflammatory panels, cfDNA methylation) rather than purely by clinical phenotype. This mirrors developments in oncology and rheumatology. ### 4.3 The "Occult Genetic" Frontier With the demonstration of somatic mosaicism (PMID: 41986690), the boundary between "familial" and "sporadic" ALS is increasingly blurred. Long-read sequencing and deep tissue sequencing may reveal that a larger fraction of "sporadic" cases carry somatic or very low-penetrance variants that could be druggable with ASOs or gene-targeted therapies. --- ## 5. Recommended Sub-Population for a Focused Trial ### **Primary Recommendation: NfL-High, TDP-43-Positive, Rapidly Progressive Sporadic ALS** **Rationale:** - **Measurable biomarker:** Serum/CSF NfL is robustly elevated in most rapidly progressive sALS cases and correlates with shorter survival (high event rate). - **Clear mechanistic link:** NfL reflects active neuroaxonal injury, providing a pharmacodynamic readout. - **Feasibility:** NfL can be measured at baseline from blood/CSF, allowing prospective enrichment. - **Precedent:** NfL was a key secondary and exploratory endpoint in the Tofersen (*SOD1*) and Tofersen-combination trials, demonstrating regulatory acceptability. - **Exclusion clarity:** By requiring elevated NfL and excluding known ALS gene mutations, this selects a homogeneous sporadic cohort. **Proposed trial design features:** - **Inclusion:** Definite/probable sALS (El Escorial revised), disease duration <18 months, serum NfL > upper quartile of validated reference range, <80% predicted FVC. - **Exclusion:** Known pathogenic *SOD1*, *C9orf72*, *FUS*, *TARDBP* variants (to ensure sporadic cohort purity). - **Primary endpoint:** Change in ALSFRS-R slope vs. historical matched control; co-primary or key secondary: percentage change in NfL from baseline at 6 months. - **Mechanistic enrichment:** Add CSF inflammatory panel or cfDNA methylation signature (per PMID: 41928938) for exploratory subgroup analysis. **Alternative / Complementary Sub-Population:** ### **Axonal Transport-Deficient sALS with Elevated pNfH and Early Distal Weakness** **Rationale:** - Supported by convergent evidence across genetic models (PMID: 41890591) and direct genetic link via *KIF5A* (PMID: 41760955). - Plasma phosphorylated neurofilament heavy chain (pNfH) may be a more specific axonal injury marker than NfL. - Distal-onset, rapidly progressive cases may represent a dying-back axonopathy phenotype more likely to respond to transport-restoring therapies. --- ## 6. Evidence Summary Table | Subgroup | Basis | Strength of Evidence | Trial Tractability | |----------|-------|---------------------|-------------------| | TDP-43 proteinopathy | Neuropathology | Strong | Low (target not yet druggable) | | Bulbar vs. limb onset | Clinical phenotype | Moderate | Low (phenotype may be epiphenomenal) | | ALS-FTD overlap | Clinicopathological | Strong | Moderate | | NfL-High | Fluid biomarker | Strong | **High** | | Fast vs. slow progressors | Clinical trajectory | Moderate | Moderate | | Somatic mosaicism | Genetics/postmortem | Emerging (2% of sALS) | Emerging (requires tissue sequencing) | | Autoimmune/anti-GM1 | Serology | Weak-to-moderate | Moderate (needs better stratification) | | Oxidative stress/excitotoxicity | CSF/markers | Moderate | Low | | Microbiome/metabolic | Metagenomics/metabolomics | Weak-to-moderate | Low | | Environmental exposure | Epidemiology | Moderate | Low (etiological, not therapeutic) | | Axonal transport defect | Genetic/models/biomarkers | Moderate-to-strong | **Moderate-to-High** | --- ## 7. Gaps and Future Directions 1. **Antemortem TDP-43 detection:** PET ligands or CSF assays for TDP-43 species would revolutionize stratification by confirming pathological subtype during life. 2. **Somatic genetic screening in accessible tissues:** Transition from postmortem brain sequencing to skin fibroblast, CSF cell, or blood-based deep sequencing. 3. **Multi-omics integration:** Combining NfL, epigenetic signatures (cfDNA methylation per PMID: 41928938), transcriptomics, and metabolomics to define molecular endotypes rather than single-biomarker subgroups. 4. **Longitudinal rate modeling:** Better methods to distinguish intrinsic biology from disease stage in defining "fast" vs. "slow" progressors. 5. **Pre-symptomatic cohorts:** Identification of at-risk individuals (e.g., first-degree relatives, elevated polygenic risk scores) to test preventive strategies in specific biological subgroups. --- ## 8. Conclusion Sporadic ALS is etiologically heterogeneous, but this heterogeneity is increasingly tractable through biomarker-based stratification. The most mature and actionable hypothesis is that **NfL-elevated, rapidly progressive sALS** represents a distinct biologically active subgroup that can be identified prospectively and used to enrich clinical trials. The emerging identification of **somatic mosaicism** and **axonal transport defects** opens new frontiers for precision medicine in what has traditionally been the most intractable 90% of cases. A trial strategy that combines NfL stratification with exclusion of known genetic causes, and explores axonal transport biomarkers as secondary stratifiers, offers the best near-term probability of success. --- > **Note:** This assessment synthesizes peer-reviewed evidence as of 2026, including recent genomic and biomarker studies (PMIDs: 41986690, 41928938, 41890591, 41760955, 41752118, 41750236, 41810938, 41839426). Web search tools were unavailable for this synthesis; citations are drawn from retrieved PubMed records and established biomedical knowledge.